Stock Spotlight Archives - Page 62 of 392

FridaySep 08, 2023 12:21 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable and ‘strategically important’ in many ways. First, it is the company’s 35th overall granted patent worldwide and the 13th granted in the United States. Second, a total of 30 claims were awarded within this patent,…

FridaySep 08, 2023 11:46 am

QualityStocksNewsBreaks – Eloro Resources Ltd.’s (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) Recent Models Suggest Potential Access to High-Grade Deposit

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mining company, is now embarked on the process of finalizing the release of its initial mineral resource estimate (“MRE”) report, which will seek to provide the market with further granularity as to the Iska Iska property’s viability as a commercial mining operation going forward. “Previously exploited by artisanal miners in the early 1960s, repeated surveys of Eloro’s Iska Iska and Mina Casiterita properties – the latter situated to Iska Iska’s immediate southwest, have outlined the appearance of an extensive, near surface, magnetic intrusive body spread across the two sites.…

FridaySep 08, 2023 11:25 am

QualityStocksNewsBreaks – GEMXX Corp. (GEMZ) Eyes Promising Start to Expected ‘Highly Lucrative’ First Year of Gold Mining

GEMXX (OTC: GEMZ), a mine-to-market global jewelry producer, is ramping up its capacity for gold ore processing at one of its Canadian assets, enthusiastic over the better-than-expected amount of ore produced from stockpiled surface material. “GEMXX’s Snow Creek Mine property in British Columbia completed site preparation for gold processing last year and mobilized equipment in May to begin bringing the property into full production. GEMXX reported the first production of gold from the site on Aug. 15 as ore collected from a 4,500-cubic-yard sample during construction of the facility was ‘cleaned out.’ The operation yielded 38.73 ounces of gold, amounting…

FridaySep 08, 2023 11:09 am

QualityStocksNewsBreaks – GolfLync Inc.’s User-Friendly and Feature-Rich Platform Driving Exceptional Growth, Engagement

GolfLync, the company behind the GolfLync app – a social network for matching golf games and players, is soaring due to its unique and feature-strong ability to bring together people who love golf, a sport that is experiencing a post-pandemic revival. “The app (available as a free download on the Apple App Store and the Google Play Store) is powered by an intelligent algorithm that brings golfers together based upon a balanced range of factors, including handicap, preferred playing style, and location, along with various related interests and specifications. The app readily supports everything from matching individual partners to building…

WednesdaySep 06, 2023 3:18 pm

QualityStocksNewsBreaks – Why RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(R) (‘RVL-1201’) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ(R) in September 2020 to a limited number of eye care professionals, with commercial operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties,” a recent article reads. “In February 2022, UPNEEQ(R) was launched into the medical…

FridaySep 01, 2023 3:45 pm

QualityStocksNewsBreaks – Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) Looking to Improve North America’s Graphite Infrastructure Efficiencies to Meet Surging Demand

Reflex (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) is advancing its flagship Ruby Graphite Project in Beaverhead County in southwestern Montana. “With its ‘mine-to-market’ strategy, Reflex aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications… Preliminary results from the TDEM and magnetic survey have demonstrated promising anomalies, indicating the presence of conductive structures, several new anomalies, and potential graphite mineral deposits within the Ruby Graphite property. The survey data will be integrated with existing…

FridaySep 01, 2023 2:43 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for Eli Lilly and Company’s (NYSE: LLY) acquisition of DICE Therapeutics Inc. (NASDAQ: DICE), a biopharmaceutical company that develops oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in…

FridaySep 01, 2023 1:09 pm

QualityStocksNewsBreaks – Why Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Is ‘One to Watch’

Prospera (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation, and development company focusing on conventional oil and gas reservoirs in Western Canada, uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery. “Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8%…

FridaySep 01, 2023 12:55 pm

QualityStocksNewsBreaks – GolfLync Inc.’s Pebble Beach Sweepstakes Provides Once-in-a-Lifetime Opportunity for Golf Enthusiasts

GolfLync, the company behind the GolfLync app – a social network for matching golf games and players, previously announced the launch of the GolfLync Pebble Beach Sweepstakes. “This exciting sweepstakes gives golf enthusiasts a chance to win a dream golf trip to the iconic Pebble Beach Resorts, renowned as the No. 1 Golf Resort in America… As the greatest public golf course in America, as rated by Golf Digest, Pebble Beach has a rich history of hosting prestigious tournaments, including the U.S. Open and, for the first time in 2023, the U.S. Women’s Open. This sweepstakes provides a once-in-a-lifetime opportunity…

FridaySep 01, 2023 12:09 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (‘NSCLC’). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed…

Site Search

Company Search

Category: Stock Spotlight